SITGEC would like to congratulate Fondazione Telethon and HSR-TIGET on the milestone achievement of the FDA approval of WAS ex vivo gene therapy. Please see below their statement: We are honoured to share a moment of profound significance for us, for patients, families, and the scientific community.    The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for  Waskyra , the  first gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS) ....

We would like to bring to your attention the upcoming  EMBO Workshop  titled “CRISPR-Cas: from biology to therapeutic applications”,...

Fondazione Telethon launches a new training initiative for early-career scientists at its flagship Institutes Fondazione Telethon is a...